More than six months after the outbreak of the pandemic that has infected more than 12 million people today and killed more than 500.000 worldwide, the clinical trials of the world's first alleged coronavirus vaccine have been successfully completed.
Clinical trials of the world's first volunteer vaccine at Covid-19 carry the Moscow plaque. The first Sechenov State Medical University, agencies say, has successfully completed the tests. Vadim Tarasov, director of the Institute of Translational Medicine and Biotechnology, also provided dates for the volunteers' resignations. The two groups involved will return home on July 15th and July 20th.
Just a month away
The university started clinical trials on the vaccine (produced by the Russian Institute of Epidemiology and Microbiology in Gamalei) just on June 18. A nose seems short time, give me the ignorant if you think.
Second Alexander Lukashev, director of the Institute of Medical Parasitology, Tropical and Vector-Borne Diseases at Sechenov University, the goal of this phase of the study was to show the safety of the vaccine for human health, and the result was excellent.
The safety of the vaccine is confirmed. Corresponds to the safety of all vaccines that are currently on the market
“In a pandemic situation we acted not only as an educational institution but also as a center for scientific and technological research,” Tarasov noted.
Vaccine at Covid-19, the other "runners"
From the news that arrives, in short, it seems that Russia has "won the race" of the tests. The possible primacy of effectiveness remains to be assessed. However, there are many companies and institutions around the world that are trying to improve the production and development of a potential Covid-19 vaccine as soon as possible.
Gilead Sciences, researchers from the University of Oxford and and the American biotechnology company Modern are at the forefront of developing a Covid-19 vaccine.
More than they are, according to news, the Covid-19 vaccine candidate is expected to BionTech SE and Pfizer Inc will seek regulatory approval by the end of 2020. The experimental vaccine, which has shown promising results, is expected to move to a large study involving 30.000 healthy participants by the end of the month, pending a regulatory hint.
